Greystone Associates, Dec 2010 DeliveringDrugs by Inhalation Advances in drug formulation and inhalation device design are creating new opportunities for inhaleddrug delivery as an alternative to oral and parenteral delivery
Business Insights, Feb 2010, Pages: 154
Delivering Opportunities in the InhalableDrugs Market: Innovative formulations and devices "The delivery of drugs using inhaled formulations is currently heavily underexploited except
Greystone Associates, Jan 2012 InhaledDrug Delivery: Devices, Indications, Therapeutics, Markets and Forecasts Advances in drug formulation and inhalation device design are creating new opportunities for inhaleddrug delivery
Greystone Associates, May 2010
Pulmonary Inhalers & Systemic Drug Delivery: Devices, Drugs, Therapeutics, Market Factors & Forecasts Advances in drug formulation and inhalation device design are creating new opportunities
Greystone Associates, Jan 2012
Dry Powder Inhalation: Technology, Devices, Markets and Opportunities Advances in drug formulation and inhalation device design are creating new opportunities for inhaleddrug delivery
Greystone Associates, Jan 2012 Drug Self-Administration Markets to 2016 While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered orally. Because
Greystone Associates, May 2009, Pages: 100
Inhaled CNS Therapeutics - Markets & Opportunities Deliveringdrugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS
GBI Research, Sep 2011, Pages: 120
Drug Delivery Device Market to 2017 - Metered Dose Inhalers and Infusion Pumps to be Key Revenue Generators Drug Delivery Device Market to 2017 - Metered Dose Inhalers and Infusion Pumps to be Key
Business Insights, Oct 2011, Pages: 92
technological developments in oral, injectable, pulmonary, and transdermal drug delivery and assess which will be most suitable for you.
Highlights:
- Novel formulations deliver superior returns on investments
Jain PharmaBiotech, May 2012, Pages: 345
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders
Jain PharmaBiotech, May 2012, Pages: 264
implantation. Gene therapy would be a more physiologic approach to deliver vasoprotective molecules to the site of vascular lesion. Gene therapy is not only a sophisticated method of drug delivery; it may
Business Insights, July 2011, Pages: 147
Drug Delivery Innovations Driving Improved Patient Compliance This report gives in depth coverage of the factors driving patient non compliance. The report then goes on to describe and analyse key
Taiyou Research, Sep 2011, Pages: 150
systems analyzed include inhalationdrug delivery systems, implantable and transdermal drug delivery systems, oral drug delivery systems and parenteral or injectable drug delivery systems.
- Overview
Takeda Pacific, Sep 2006, Pages: 163
stents, PEG, nanotechnology, liposomes, monoclonal antibodies, gene delivery, and implants, which all contribute to the many ways that drugs or therapies can be delivered. Drug delivery systems
Business Insights, June 2007, Pages: 129
that can help your organization deliver enhanced clinical and commercial output.
Drug Repositioning Strategies
Innovative strategies to boost pipeline productivity
- The number of deals between pharma
Jain PharmaBiotech, May 2012, Pages: 754
delivered to the lungs
Nanoparticle drug formulations for spray inhalation
Nanobiotechnology for improving insulin delivery in diabetes
Inhalation of glucose-sensitive NP for regulated release of insulin
Business Insights, Nov 2006, Pages: 137
level of innovation in this sector is evolving at a fast pace with products such as Pfizer’s inhaled insulin, Exubera, gaining US approval in January 2006.
‘Innovation in Drug Delivery’ provides
Informa Healthcare, May 2008, Pages: 1248
Mist Inhaler for DeliveringDrugs to the Lungs. Metered Dose Inhalation Technology. Intellectual Property. US Intellectual Property Issues Relating to Modified Release Products. India Intellectual
Smithers Information Ltd, May 2009
and pharmaceutical perspective explored through expert delivered papers. Other sessions on leachables and extractables in OINDP, Parenteral and Opthlamic Drug Products (PODP), medical devices, dermal membrane
